Capricor Therapeutics’ (CAPR) Buy Rating Reaffirmed at HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $77.00 price objective on the biotechnology company’s stock.

Separately, Cantor Fitzgerald lifted their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Trading Down 7.7 %

NASDAQ CAPR opened at $12.65 on Tuesday. The company has a market cap of $575.20 million, a P/E ratio of -11.93 and a beta of 4.08. The company has a fifty day simple moving average of $14.40 and a 200 day simple moving average of $13.93. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40.

Hedge Funds Weigh In On Capricor Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CAPR. Magnus Financial Group LLC bought a new stake in shares of Capricor Therapeutics in the fourth quarter valued at approximately $276,000. State Street Corp raised its holdings in Capricor Therapeutics by 27.8% during the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock valued at $7,792,000 after acquiring an additional 111,291 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Capricor Therapeutics by 419.5% during the third quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company’s stock worth $855,000 after acquiring an additional 45,381 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Capricor Therapeutics in the third quarter worth $3,806,000. Finally, Black Diamond Financial LLC purchased a new position in shares of Capricor Therapeutics in the fourth quarter valued at $3,833,000. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.